Menu
Recruiting NCT07481149

Trial of a Virtual Exercise-based Rehabilitation Program to Treat Persistent Chemotherapy-Induced Peripheral Neuropathy (CIPN)

Phase III Interventional Chemotherapy-induced Peripheral Neuropathy (CIPN)

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: EX-CIPN.
Who it may be relevant to
Registry conditions: Chemotherapy-induced Peripheral Neuropathy (CIPN). Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Canada
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

A Pragmatic Randomized Controlled Trial of a Virtual Exercise-based Rehabilitation Intervention for Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN).

Overview

The purpose of this study is to determine the effectiveness of the EX-CIPN program in reducing the strength of CIPN symptoms and CIPN-related disability and improving the ability to complete everyday activities. This will be done by determining whether it is better to receive the EX-CIPN program or better to receive no additional intervention. To do this, some of the participants in this study will get EX-CIPN and others will receive usual care. Those who receive usual care will be offered EX-CIPN upon study completion. The main question it aims to answer is: • Is EX-CIPN effective in improving CIPN symptoms for cancer survivors experiencing persistent CIPN? Participants in both study groups will be asked to: • Complete assessments at baseline, immediately post-intervention, and 3-months post-intervention Participants in the EX-CIPN group will be asked to: * Complete an additional aassessment at 6-months post-intervention * Complete a 10-week remote, individualized exercise program * Receive health coaching calls on weeks 2, 3, 4, 6, and 8 of the intervention * Wear a FitBit throughout the study to track physical activity and promote behaviour change

Interventions

  • Behavioral EX-CIPN
    The 10-week intervention includes: Individualized Exercise Program: Each participant will receive an individualized progressive exercise program that includes cardiovascular and strength training as well as balance and desensitization exercises specific to CIPN symptoms. Remote Monitoring: Fitbit™ devices will be used to monitor patients' physical activity over the duration of the program. Fitness trackers can promote behaviour change. Remote Person-to-Person Clinical Support: Participants will

Primary outcome measures

  • CIPN Symptoms [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]
Secondary outcome measures (6)
  • CIPN-related disability [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]
  • Strength (Upper Body) [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]
  • Strength (Lower Body) [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]
  • Balance [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]
  • Gait Speed [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]
  • Aerobic Functional Capacity [Time frame: Baseline, post-intervention (10 weeks), 3-months post-intervention (22 weeks), 6-months post-intervention (34 weeks)]

Eligibility criteria

Inclusion criteria

  • diagnosed with any type of cancer
  • received chemotherapy treatment as part of curative-intent therapy (no minimum dose)
  • >6 months following chemotherapy completion with no current plans for further chemotherapy
  • report Grade 1 or higher on the numbness and tingling severity item of the Common Terminology Criteria for Adverse Events (CTCAE) v 5.0
  • neuropathic pain 3 or higher on the Neuropathic Pain 4 (DN4) (interview)
  • capable of ambulation and transfers (with or without gait/transfer aid) (ECOG score 0-2)
  • are able to communicate sufficiently in English to complete intervention, questionnaires, and consent
  • have access to and able to operate videoconferencing

Exclusion criteria

  • currently meeting all recommendations from the physical activity guidelines for cancer survivors
  • have any neurological conditions influencing cognition (i.e. dementia, Alzheimer's) and preventing safe or appropriate engagement with exercise recommendation
  • have neuropathy that pre-existed chemotherapy receipt (i.e. diabetic neuropathy)
  • currently enrolled in other rehabilitation or exercise-based interventions

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Canada · 1 center
  • ELLICSR: Health Wellness and Cancer Survivorship Centre — Toronto

Identifiers

NCT: NCT07481149 · 25-5957

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗